Dimerix Strengthens Phase 3 Study Outlook with Positive Statistical Review
Dimerix Limited (ASX: DXB) reported a positive milestone in its Phase 3 ACTION3 clinical trial, confirming that the study remains strongly positioned to achieve its primary objective. An independent blinded statistical review verified that the trial maintains over 90% power to demonstrate a meaningful reduction in proteinuria, a key indicator in kidney disease treatment.
The company will continue the study through to its final endpoint, focusing on strengthening the pathway toward regulatory approval for its lead drug candidate, DMX-200. Patient recruitment for the adult cohort has been completed, while enrolment of younger participants remains ongoing. Importantly, regulatory support for proteinuria as a primary endpoint enhances the likelihood of approval and reduces development risk. The update reinforces confidence in the trial’s design and the company’s strategy to deliver a potential treatment for patients with rare kidney disease.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Dimerix Strengthens Phase 3 Study Outlook with Positive Statistical Review
Dimerix Limited (ASX: DXB) reported a positive milestone in its Phase 3 ACTION3 clinical trial, confirming that the study remains strongly positioned to achieve its primary objective. An independent blinded statistical review verified that the trial maintains over 90% power to demonstrate a meaningful reduction in proteinuria, a key indicator in kidney disease treatment.
The company will continue the study through to its final endpoint, focusing on strengthening the pathway toward regulatory approval for its lead drug candidate, DMX-200. Patient recruitment for the adult cohort has been completed, while enrolment of younger participants remains ongoing. Importantly, regulatory support for proteinuria as a primary endpoint enhances the likelihood of approval and reduces development risk. The update reinforces confidence in the trial’s design and the company’s strategy to deliver a potential treatment for patients with rare kidney disease.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au